Sorcero raised a $42.5 million Series B led by NewSpring Capital

NewSpring Capital led a $42.5 million Series B to expand the platform across life sciences. Medical affairs, safety and scientific communications teams at large pharmaceutical companies use its medically tuned AI to surface evidence and capture insights.

We backed Sorcero because medical affairs has had few good tools for the volume of evidence it is expected to read, and accuracy and traceability are not optional in that industry. Working with a meaningful share of the largest global pharma companies gave us confidence that the product earns trust in a demanding market, and this round funds the expansion on top of it.

Back to the clippings file